Halozyme Therapeutics Inc. buy Benchmark Co.
Start price
16.04.24
/
50%
€36.23
Target price
16.04.25
€46.98
Performance (%)
-0.55%
Price
24.04.24
€36.53
Summary
This prediction is currently active. The BUY prediction by Benchmark_Co_ for Halozyme Therapeutics Inc. is nearly unchanged. This prediction currently runs until 16.04.25. The prediction end date can be changed by Benchmark_Co_ at any time. Benchmark_Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Halozyme Therapeutics Inc. | 0.717% |
iShares Core DAX® | 0.961% |
iShares Nasdaq 100 | 2.626% |
iShares Nikkei 225® | 0.217% |
iShares S&P 500 | 1.540% |
Comments by Benchmark_Co_ for this prediction
In the thread Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Stopped prediction by Benchmark_Co_ for Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€31.35
19.01.24
19.01.24
€45.94
19.01.25
19.01.25
16.52%
24.04.24
24.04.24
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€33.23
20.10.23
20.10.23
€47.17
20.10.24
20.10.24
9.93%
24.04.24
24.04.24